Neuroendocrine host factors and inflammatory disease susceptibility. by Ligier, S & Sternberg, E M
Neuroendocrine Host Factors and Inflammatory DiseaseSusceptibility
Sophie Ligier and Esther M. Sternberg
Clinical Neuroendocrinology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland USA
The etiology of autoimmune diseases is multifactorial, resulting from a combination of genetically
predetermined host characteristics and environmental exposures. As the term autoimmune implies,
immune dysfunction and dysregulated self-tolerance are key elements in the pathophysiology of all
these diseases. The neuroendocrine and sympathetic nervous systems are increasingly recognized
as modulators of the immune response at the levels of both early inflammation and specific
immunity. As such, alterations in their response represent a potential mechanism by which
pathologic autoimmunity may develop. Animal models of autoimmune diseases show pre-existing
changes in neuroendocrine responses to a variety of stimuli, and both animal and human studies
have shown altered stress responses in the setting of active immune activation. The potential role
of the neuroendocrine system in linking environmental exposures and autoimmune diseases is
2-fold. First, it may represent a direct target for toxic compounds. Second, its inadequate function
may result in the inappropriate response of the immune system to an environmental agent with
immunogenic properties. This article reviews the relationship between autoimmune diseases and
the neuroendocrine system and discusses the difficulties and pitfalls of investigating a physiologic
response that is sensitive to such a multiplicity of environmental exposures. Key words:
autoimmunity, eosinophilia myalgia syndrome, Fischer rats, hypothalamic-pituitary-adrenal axis,
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It is increasingly recognized that autoimmune
diseases have a multifactorial etiology.
Although genetic studies have identified sev-
eral susceptibility loci in a variety ofinflam-
matory disorders (1), twin studies in
rheumatoid arthritis (RA) and systemic
lupus erythematosus (SLE), for example,
have at best shown concordance rates
between 15 and 30% (2,3). This under-
scores the need for better understanding of
the environmental factors involved in
triggering autoimmune diseases.
These diseases, although clinically very
diverse, are generally believed to result from
immune dysregulation and in particular
breakdown ofself-tolerance. The immune
response is regulated through a number of
mechanisms, each ofwhich, ifaltered, could
result in the development of disease.
Neuroendocrine and sympathetic nervous sys-
tem responses also play a role in such modula-
tion ofhost immune responses to antigenic
exposure. Although this is arelativelynew area
ofscientific interest, the potential role played
by the neuroendocrine system in autoimmu-
nity has been considered since the 1940s. The
finding of initially remarkable therapeutic
effects with glucocorticoids in RA early on
raised the issue ofadrenal hormone insuffi-
ciency and ofhypothalamic-pituitary-adrenal
(HPA) axis dysfunction as an etiologic factor
ofthe disease (4). More recently, evidence in
both human autoimmune processes and in
their animal models has been gathered to sup-
port the role ofthe neuroendocrine system in
thedevelopment ofautoimmunity.
The neuroendocrine system becomes
particularly relevant when discussing the
impact ofthe environment on the immune
system and the susceptibility to autoimmune
processes. Indeed, in addition to affecting the
immune system at several levels, neuroen-
docrine activation occurs in response to a
wide range of stimuli. Although the term
environmental exposure classically designates
exposure to potential toxic chemicals or infec-
tious agents, triggers of the neuroendocrine
response are very diverse. A wide variety of
physical and psychologic stimuli can activate
both the neuroendocrine and sympathetic
nervous systems, eliciting a cascade ofevents
collectively referred to as the stress response
(5). The immediate and chronic changes that
this sequence ofphysiologic reactions pro-
vokes help the organism cope with the envi-
ronmental challenges. Conversely, a relative
imbalance ofthe hormonal stress response to
an environmental exposure may represent a
contributing factor in the development of
inflammatory and autoimmune disease. Sex
hormones, prolactin secretion, and peripheral
neural activation are all additional modulators
of the body's response to antigenic stimuli.
The development ofan autoimmune process
is thus likely the result ofa critical exposure
to environmental factors combined with mul-
tiple host susceptibility characteristics, includ-
ing neuroendocrine responsiveness. Evidence
in animal models and human disease indi-
cates that both the neuroendocrine system
and putative environmental (often infectious)
triggers play a key role in the pathophysiology
of several autoimmune diseases. These
include RA, SLE, multiple sclerosis (MS),
and Sjogren syndrome.
In this article, before summarizing the
data implicating the neuroendocrine system in
the pathophysiology ofautoimmunity, we will
first review some concepts on neuroendocrine
activation and its effects on the organism.
The Stress Response
Following exposure to a stressful stimulus,
sympathetic nervous system activation causes
increases in heart rate, sweating, and muscle
blood flow. Production of central corti-
cotropin-releasing hormone (CRH) and acti-
vation of the locus coeruleus result in
behavioral changes such as increased focused
attention. Acutely, these behavioral and phys-
iologic responses are collectively referred to as
the fight-or-flight response. The HPA axis is
quickly activated within minutes after expo-
sure to a variety ofstressors, either primarily
psychologic (performance tasks), or physical
in nature (exercise, trauma, or thermal, chemi-
cal/infectious/immune). The hypothalamus
secretes the neurohormones CRH and argi-
nine vasopressin, which then signal the pitu-
itary gland to produce corticotropin (ACTH).
ACTH in turn stimulates adrenal gland gluco-
corticoid production. In addition to effects on
multiple organ systems including immune
cells, glucocorticoids feed back on and
suppress the HPAaxis cascade at everylevel.
Stressful stimuli also activate the brain
stem, resulting in an increased sympathetic
nervous system outflow to the periphery (6).
Hypothalamic CRH can stimulate brain stem
noradrenergic regions and increase their
sympathetic activation. In turn, brain stem
adrenergic outflow can further signal the
hypothalamus to secrete CRH.
The resulting stress response varies
depending on the stimulus to which it is
exposed. Not surprisingly, the response to
psychologic stressors is dependent on the
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individual's subjective perception ofthe event
(7). Within the category ofprimarily physical
stressors, the HPA axis response differs from
one stimulus to another. Intermittent elec-
trical foot shock in rats activates different
stress-responsive central nervous system neu-
rotransmitter pathways than a systemic inter-
leukin (IL)-1 challenge (8). Similarly,
hemorrhage, insulin injection, subcutaneous
formaldehyde injection, exposure to cold, and
immobilization will all elicit different patterns
ofepinephrine andACTH secretion (9). The
nature, route ofexposure, and duration ofthe
immune challenge also determine the HPA
axis response pattern (10).
The duration ofanystressful stimulus is an
important determinant ofthe resulting HPA
axis response. Though it is not uniform in all
rat species, ACTH secretion control shifts
from CRH to arginine vasopressin (AVP) in
the presence ofchronic inflammatory stress
(11). This may be due to differential sensitiv-
ity of CRH and AVP secretion to negative
feedback by corticosterone. Thus, hypothala-
mic paraventricular nucleus glucocorticoid
receptor (GR) mRNA decreases following
repeated acute stress (12). Similar patterns
have been demonstrated in human chronic
conditions such as MS. Patients with MS have
baseline hypercortisolemia, a blunted ACTH
response to AVP, and a normal ACTH
response to CRH. Ofnote, subjects in this
study did notexhibit signs ofincreased periph-
eral inflammation, e.g., plasma sedimentation
rates, IL-6, and IL-1P1 levels were not increased
(13). However, these studies suggest that
chronic exposure to stress can result in read-
justments ofcentral stress-responsive neuro-
transmitter and neuroendocrine systems
normally activated during acute stress.
Furthermore, peripheral immune signaling to
the central nervous system likely changes over
the course ofchronic inflammation, poten-
tially resulting in a different HPA axis
response. Thus, patterns ofcytokine secretion
by peripheral blood mononuclear cells differ
between patients with early and long-standing
RA (14). Thus, these physiologic stress
response changes in the context ofchronic
inflammation complicate data interpretation of
neuroendocrine responses in inflammatoryand
autoimmune diseases. It is therefore difficult to
establish a causal relationship between HPA
axis hyporeactivity and predisposition to
inflammatorydisease in the context ofongoing
established chronic inflammation.
Chronic stress exposure also results in
quantitative changes in neuroendocrine acti-
vation in response to a second, different stim-
ulus. Forexample, dampening ofthe response
to acute stimulation occurs in animals with
chronic inflammation (15). Immobilization
stress in rats with adjuvant-induced arthritis
will result in increased hypothalamic CRH
mRNA expression at 1 week following the
injection ofadjuvant but not at 2 weeks when
the arthritis begins to manifest itself (16).
This blunted response is not observed when
the second acute stressor is inflammatory (17).
Apre-existing stressor, physical or psychologic,
can also dampen the inflammatory response to
an immune challenge (18,19).
Interactions between the
Immune and Neuroendocrine
Systems: Bidirectional
Communication Pathways
The immune and central nervous systems
communicate at multiple levels and recipro-
cally influence one another (20-22). The
immune response to tissue injury can be bro-
ken down into two steps. Initially, nonspecific
inflammation is characterized by vasodilata-
tion with influx ofpolymorphonuclear white
blood cells and their release of a variety of
inflammatory mediators. This results in local-
ized swelling, redness, and pain. This may be
resolved or lead to a chronic phase ofinflam-
mation when the host's immune system
mounts a specific attack on foreign antigens.
Autoimmunity designates the process by
which the immune system targets self-anti-
gens, and can result in a chronic inflammatory
process if it goes unchecked by the host's
immune regulatory mechanisms. The inflam-
matory mediators generated during these
processes signal the brain through a variety of
routes. Cytokines produced systemically and
in localized foci ofdisease such as the syn-
ovium in RA play an important role in the
pathogenesis ofautoimmune diseases (23).
These cytokines activate neuroendocrine
responses by crossing the blood-brain barrier
at leaky points (the circumventricular organs),
through specific active transport mechanisms
(24) or by the actions ofsecond messengers
such as nitric oxide (25). Inflammatory stim-
uli can also activate the stress response ofthe
central nervous system through afferent
peripheral neural signaling. Thus, peritoneal
cytokines can cause early rapid activation of
the nucleus of the tractus solitarius in the
brain stem (26,27) viavagal stimulation.
The nervous system in turn regulates the
immune system via many routes (20).
Systemically, the neuroendocrine HPA axis
hormonal response modulates both non-
specific and specific immune responses, pri-
marily through the effects of cortisol.
Exogenous corticosteroids have long been used
in humans as immunosuppressors. It is
increasingly recognized that physiologic con-
centrations ofglucocorticoids also regulate
immune function (28) and function as
immunomodulators. At lower concentra-
tions, corticosteroids cause relatively greater
suppression ofthe proinflammatory cytokines
tumor necrosis factor-tx, and IL-1 (29,30)
compared to the anti-inflammatory cytokine
IL-10 (31), and result in a shift in immune
response from aT-helper 1 (Thl) cellular-type
to aTh2humoral-type response.
The increased neural sympathetic output
resulting from activation of the stress
response also likely modulates the immune
response. Thus, the sympathetic nervous sys-
tem plays a role in modulating inflammatory
responses through the regional innervation of
immune organs such as the spleen, thymus,
andlymph nodes (32). Sympathetic denerva-
tion in animals affects regional inflammation
differentlydepending on the site and mode of
the intervention (33,34). The natural splenic
sympathetic denervation associated with
aging mayplay a role in the immunosuppres-
sion observed with aging (35). The re-estab-
lishment ofsplenic innervation associatecd
with deprenyl administration leads to the
reconstitution ofsplenic immune cell func-
tion in aged or denervated animals (36).
The nervous system also regulates local
acute inflammatory responses through the
action ofsympathetic postganglionic neurons
and their effect on fluid extravasation (37,38)
and through the release oflargely proinflam-
matoryneuropeptides such as CRH, substance
P, and vasoactive intestinal polypeptide. They
are released at nerve endings or synapses at the
site of inflammation or can be produced
directlybyimmune cells. Both peripheral sym-
pathetic noradrenergic nerves and substance P-
containing nerves play a role in joint
inflammation (39). Therefore, some neu-
ropeptides such as CRH can be either pro- or
anti-inflammatory (40), depending on
whether they are localized centrally or periph-
erally. Central CRH suppresses immune
responses through activation ofthe HPA axis
and release ofglucocorticoids; peripheral CRH
released at nerve terminals isproinflammatory.
Animal Models of
Inflammatory Disease,
Autoimmunity, and Differential
Neuroendocrine Function
Avariety ofanimal models have been used to
study autoimmune diseases. The assessment
oftheir stress response and in particular of
their HPA axis activation characteristics has
been one of the areas ofstudy into disease
pathophysiology.
LewisandFscerRasi InbredStains
atOpposite EndsoftheSpecrum of
I n rySusceptibility
Lewis (LEW/N) and Fischer (F344/N) rats are
major histocompatible inbred rat strains that
differ only at one minor histocompatibility
locus (the Neu-1 locus). These strains have
been used repeatedly to study inflammatory
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disorders, as LEW/N rats can develop avariety
of autoimmune conditions ranging from
uveitis and arthritis to experimental allergic
encephalomyelitis (EAE), depending on the
antigenic stimulus to which they are exposed
(20). The neuroendocrine response was ini-
tially studied in these rats following their
exposure to group A streptococcal cell-wall
peptidoglycan polysaccharide (SCW).
Following SCW injection, female LEW/N
rats develop a progressive erosive arthritis
resembling human RA clinically, radiologi-
cally, and histologically (41). Inflammation-
resistant F344/N rats lie at the other end of
the inflammatory phenotype spectrum, devel-
oping only minimal disease in response to
this inflammatory stimulus (41). Outbred
Harlan Sprague-Dawley rats exhibit interme-
diate inflammatorysusceptibility.
The degree of HPA axis activation
response differs significantly between these
strains. This difference appears to play an
important role in the control ofearly inflam-
mation, as female athymic LEW/N rats
develop the full acute inflammatory response
to SCW administration but do not progress
to chronic arthritis (42). Compared to
F344/N rats, LEW/N rats have blunted
plasma ACTH and corticosterone responses
to a variety of stimuli including SCW,
recombinant human IL-la, the serotonin
agonist quipazine, and synthetic rat/human
CRH (41,43). LEW/N rats also have smaller
adrenal glands and larger thymii than
F344/N rats. Low-dose exogenous dexam-
ethasone administration significantly
decreases the severity ofarthritis in LEW/N
rats, whereas treatment ofF344/N rats with
the glucocorticoid receptor antagonist
RU486 or the serotonin antagonist LY53857
results in the development ofsevere inflam-
matory arthritis. This suggests that LEW/N
rat susceptibility to SCWarthritis is related to
a defective HPA axis responsiveness to
peripheral inflammation and that the resis-
tance ofF344/N rats may be due to a robust
HPAaxis activation pattern.
Surgical and pharmacologic manipula-
tions ofthe HPA axis in other animal models
have provided additional evidence to support
a direct cause-effect relationship between
endocrine and inflammatory disease traits.
Pharmacologic [using the glucocorticoid
receptor antagonist RU486, or the serotonin
(5-HT2) receptor antagonist LY53857] and
surgical (hypophysectomy, adrenalectomy)
interruptions ofthe HPA axis at various levels
render animal strains otherwise resistant to
inflammation highly susceptible to inflamma-
tory diseases such as EAE (44) or arthritis
(41). Treatment with dexamethasone prevents
the development ofSCW-induced arthritis
(41) and partially or completely prevents EAE
in response to myelin basicprotein (44).
Many experiments using this approach
have focused on the impact ofthese interven-
tions on the acute nonspecific phase of
inflammation. For example, adrenalec-
tomized rats show a larger and more cellular
exudate in response to intrapleural injection
ofcarrageenan, an algae extract used as a non-
specific irritant (45). F344/N rats are resis-
tant not only to the development ofchronic
erosive arthritis but are also less susceptible to
acute carrageenan-induced exudative inflam-
mation than LEW/N rats (46,47). Similarly,
the administration ofcorticosteroids decreases
the acute inflammatory response ofLEW/N
rats to the level ofthat observed in the F34/N
strain, whereas the administration ofRU486
to F344/N rats increases their inflammatory
response to levels similar to that of the
LEW/N rats (46). Surgical manipulations
that reconstitute the HPA axis also appropri-
ately modify the peripheral inflammatory
response. Thus, transplantation offetal hypo-
thalamic tissue intracerebroventricularly from
Fischer rats into inflammatory-susceptible
LEW/N rats decreases subcutaneous car-
rageenan inflammation in LEW/N rats by
over 85% (48) while increasing LEW/N
hypothalamic CRH expression and plasma
corticosterone response to lipopolysaccharide.
LEW/N rats have been used as animal
models for other autoimmune diseases.
Following the injection ofmyelin basic pro-
tein, these rats develop EAE, an illness that in
several ways resembles MS. The administra-
tion of exogenous corticosteroids, as in the
erosive arthritis model, decreases the intensity
of the disease; blockade of corticosteroid
action has the opposite effect (49).
An example ofthe use ofthis rat strain to
studyputative environmental agents was in the
study ofL-tryptophan-associated eosinophilia
myalgia syndrome (50). Treatment of
LEW/N rats with case-associated L-tryptophan
or one of its derivatives (1,1'-ethylidenebis
tryptophan) was associated with the develop-
ment ofan illness with features offasciitis and
perimyositis similar to what has been reported
inhuman pathologicspecimens (51,52).
Recent linkage studies indicate that the
inflammatory susceptibility ofthese rat strains
is polygenic (53,54). As suspected, environ-
mental factors play a large role. Thus, the
exudate volume phenotype following subcu-
taneous carrageenan administration in the
LEW/N rats has been associated with an
environmental variance of65%.
MurineLupus Models: HPAAxis
andNeuroendocrine Function
Several strains of mice have been used as
models for SLE. Although they differ in their
disease susceptibility and presentation, they
have been found to have an altered HPA axis
activation response. When compared to
non-lupus-prone mice, NZB, NZW,
(NZB/NZW)F1, and MRL/MP-prmice have
elevated baseline corticosterone levels with a
blunted increase following IL-1,B injection
(55). These characteristics are different from
those observed in the arthritis-susceptible
LEW/N rats discussed above. This is not sur-
prising, as it must be remembered that the
diseases collectively referred to as autoim-
mune in etiology are actually quite diverse in
both their clinical presentation and in their
pathophysiology. Apart from its defining clin-
ical characteristics and its response to treat-
ment, there is evidence that SLE is
characterized by a shifted Th2-type immune
response, whereas RA is primarily a Thl-
driven process (56).
The roles ofthe hypothalamic-pituitary-
gonadal (HPG) axis and prolactin in SLE
pathophysiology have also been repeatedly
questioned, both in humans and murine mod-
els. High estrogen and high prolactin states
have repeatedly been associated with increased
disease activity and mortality (57), whereas
treatment with the prolactin-suppressing drug
bromocriptine improves outcome (57,58).
Prolactin has an overall immunostimulatory
effect in these mice and appears to potentiate
the effect ofestrogen on autoantibody produc-
tion. Estrogen may exert its effects by shifting
the lymphocyte response from a Thl- to a
Th2-type response (56,59).
AvianModels ofAutoimmunity
Avian species have provided two important
models for human autoimmune diseases. Both
show altered HPA axis activation responses.
The obese strain chicken spontaneously devel-
ops autoimmune thyroiditis and is used as a
model for Hashimoto thyroiditis (60). Several
defects have been identified in this strain at
various levels in the HPA axis, and all may
contribute to its inflammatory susceptibility.
First, these chickens have elevated levels ofcir-
culating corticosteroid-binding globulin (61),
which effectively reduces the available amount
ofphysiologically active corticosterone. This is
without any measurable change in GR num-
ber and affinity or in circulating corticos-
terone levels. Second, the animals'
corticosterone response to IL-1 injection is
significantly blunted. Finally, their thymocytes
appear to be resistant to dexamethasone-
induced apoptosis. Importantly, dietary iodine
content has been found to significantly influ-
ence the onset and course ofthe illness (62).
Thus, the obese strain chicken represents a
good example ofthe multifactorial etiology of
autoimmune diseases. In particular, it illustrates
how both specific environmental exposures and
coexisting HPA axis defects contribute to the
development ofpathology.
University of California, Davis (Davis,
CA) line 200 White Leghorn chickens
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spontaneously develop a systemic fibrotic
disease that resembles scleroderma; clinical
manifestations include cutaneous fibrosis and
polyarthritis, and pathologic examination
reveals dermal fibrosis and vaso-occlusive dis-
ease (63). Additionally, these animals produce
amultiplicity ofautoantibodies. In response to
IL-1 injection, these animals mount a corticos-
terone response similar to that in normal con-
trols (64). However, levels are slower to return
to normal. ACTH levels are significantly ele-
vated compared to that in controls, suggesting
decreased adrenal responsiveness (65).
Implications ofThese
PrinciplesforSusceptibility
to Environmentally Induced
Autoimmune/lInflammatory
Diseases
These experiments illustrate several key
points. In addition to supporting the role of
the HPA axis and other neuroendocrine fac-
tors in regulating the acute nonspecific
immune respons'e to antigenic or inflamma-
tory challenge, they suggest that attenuation
of early inflammation may significantly
reduce the risk ofprogression to a chronic ill-
ness after an exposure. From the point of
view ofdisease pathophysiology, these find-
ings suggest that a hypoactive HPA axis stress
response to acute antigenic exposure is one of
the many factors predisposing subjects to the
development of a chronic inflammatory
process. They also raise the issue ofwhether
early corticosteroid treatment may be critical
in preventing an acute inflammatory response
from evolving into a chronic disease.
Furthermore, such studies indicate that a
variety ofgenetic factors, including immune-
related and other host response genes, interact
with environmental stimuli to produce a final
inflammatory disease outcome.
With regard to implications for
environmentally induced autoimmune dis-
eases, these studies suggest two mechanisms
bywhich environmental exposures may inter-
act with the neuroendocrine system and
result in pathology. First, the premorbid
degree of host HPA axis responsiveness,
largely genetically or developmentally deter-
mined, may be an important variable in gov-
erning whether the host goes on to develop
chronic autoimmune disease after exposure to
an environmental agent with immunogenic
potential. Second, exposures to environmental
agents with hormonal agonist or antagonist
properties could directly interfere with neu-
roendocrine system function, thereby altering
immune response patterns. By disrupting
the endocrine response, such agents could
indirectly contribute to the development
of autoimmune diseases. The study of
the hormonal activity of environmental
compounds, both man-made and naturally
present, has recently gained much attention.
Outside ofpharmacologic agents, compounds
with known glucocorticoid antagonist or
antagonist activity are less well studied.
However, many chemicals and plants are now
known to have estrogenic activity. Whereas
most ofthe focus has been on their peripheral
tissue activity, little is known about their cen-
tral effects on the function ofthe HPG axis.
Human HPA Axis Activation
Response Assessment:
Methods and Limitations
Most ofthe studies ofthe HPA axis response
in humans employ a combination ofdirect
plasma measurements ofACTH and cortisol
and dynamic testing ofthe axis with anterior
pituitary stimulation. Plasma hormone meas-
urements at regular intervals over 24 hr can
provide a broad quantitative estimate ofhor-
monal secretion as well as insight into poten-
tial disturbances in the circadian rhythm of
secretion. Direct pituitary stimulation with
ovine CRH represents a good test for the
assessment ofpituitary reserve. It is often per-
formed in conjunction with the infusion of
the other main anterior pituitary hormone
secretagogues to provide aglobal assessment of
anterior pituitary functional reserves. When
interpreting the results in the setting of
autoimmune diseases, it is critical to remem-
ber the multiplicity offactors that influence
the neuroendocrine response. Thus both
intrinsic patient characteristics and environ-
mental exposures such as age (66), gender
(67), ethnic background (68), weight, psychi-
atric disorders (69,70), acute and chronic dis-
ease, chronic pain syndromes, and smoking
have effects on HPA axis activation patterns.
Ofparticular relevance in thestudy ofautoim-
mune diseases is the impact ofpharmacologic
agents on HPA axis function, as these patients
are frequently on several medications.
NeuroendocrineStudies
in RheumatoidArthritis
Deficient corticosteroid production has
repeatedly been questioned as a potential fac-
tor in the pathogenesis ofRA (71-73). Initial
findings resulted from simply measuring
plasma and urinary cortisol and corticosteroid
metabolism products, but more recently a
variety ofmethods have been used to stimulate
the HPAaxis in order to bringout moresubtle
defects in the neuroendocrine activation
response. Several studies have approached the
question bymeasuringplasmaACTH andcor-
tisol levels at regular intervals (74,75). The
CRH stimulation test, along with the infusion
ofthe other anterior pituitarystimulatory pep-
tides, has also been used to study neuroen-
docrine responses in RA patients (74,76,77).
As previously noted (78), overall there appears
to be a blunting ofthe HPA axis response in
RA. A recurrent topic ofdiscussion surround-
ing the data obtained in these studies is the
concept ofrelative adequacy ofthe HPA axis
response. Thus normal circulatingACTH and
cortisol levels in the setting ofongoing sys-
temic inflammation do not necessarily indicate
an intact HPAaxis. Though most resultspoint
to intact anterior pituitary and adrenal
responses to CRH, it is also possible that the
hypothalamus in RA is unable to appropriately
react to peripheral inflammation and the stim-
ulatory neural and cytokine signals this gener-
ates. Chikanza et al. (79) addressed this issue
by studying two patient groups-RA and
chronic osteomyelitis-and assessed their cor-
ticosteroid response to a surgical stressor.
Subjects with osteoarthritis and low back pain
served as controls. Although the RA patients
maintained a circadian rhythm ofcortisol
secretion, their levels were at the lower end of
those observed in controls, and lower than
those seen on the osteomyelitis group.
Additionally, RA patients failed to show the
expected increase in cortisol postoperatively as
was observed in the osteomyelitis and
osteoarthritis groups. RA appears to be associ-
ated to an abnormal hypothalamic response to
peripheral inflammation andsurgical stress.
Ultimately, the impact of a hypofunc-
tional HPA axis on the inflammatory process
depends on the response of the peripheral
tissue to circulating glucocorticoids.
Schlaghecke et al. (80) studied GR affinity
and density in patients with active RA who
had not been treated with corticosteroids for
at least 6 months. Although a decreased
number ofperipheral lymphocyte GRs was
found, this was not associated with any func-
tional difference between the two groups in
peripheral lymphocyte cytokine production
and proliferation responses in the presence of
glucocorticoids (81).
These studies do, however, raise questions
regarding the potential role ofcorticosteroid
treatment, particularly early on in the disease
course. As discussed above, the evidence in
animal models suggests that endogenously
produced corticosteroids and their exogenous
administration are key elements in curtailing
acute inflammation and can prevent the
development ofexperimental chronic inflam-
matory processes (41). Although initial
enthusiasm for exogenous glucocorticoid
treatment in diseases like RAwas followed by
a more cautious use ofthe drug, mostly as a
result ofits side-effect profile, there is now
evidence that these agents do have an impact
on disease progression (82). Ofparticular
interest is the fact that relatively low doses of
glucocorticoids may be sufficient to alter the
courseofdisease.
Human studies also support animal
findings on the role ofthe peripheral nervous
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system in the immune response. Juvenile RA
patients have altered sympathetic system
responsiveness as measured using orthostatic
stress (83). This maybe related to an increase
in basal sympathetic tone. Additionally, the
peripheral mononuclear white blood cells in
juvenile RA show reduced response to ,-2
adrenergic stimulation, which could poten-
tially result in changes ofT-cell and mono-
cyte function. These changes could further
contribute to differential inflammatory
responses.
Neuredocrine Studies in
SjogrenSyndromeandSystemic
LupusErythematosus
While numerous studies have been conducted
to investigate the HPA axis function in RA
patients, similar questions have also been
raised in other autoimmune diseases. One of
the most prevalent autoimmune diseases that
can coexist with RA is Sjogren syndrome.
This illness predominantly affects women and
is characterized by lymphocytic infiltration of
the salivary and lacrimal glands, resulting in
clinical symptoms ofdry mouth and eyes.
Patients are usually antinuclear antibody-
positive and may have anti-Ro and/or anti-La
autoantibodies alongwith circulating rheuma-
toid factor (RF) and hypergammaglobulin-
emia. The etiology ofthe disease is unclear.
One study of 8 women with Sjogren syn-
drome showed that along with decreased
early-eveningbasal plasmaACTH and cortisol
levels, these patients also had blunted pituitary
and adrenal responses to ovine CRH com-
pared to those ofcontrols (84). The subjects
were similar in menopausal status and were
not receiving medications. It remains unclear
whether the hypoactivity ofthe stress response
preceded the onset ofthe disease orwas a con-
sequenceofongoing chronic inflammation.
Similarstudies havealso beenperformed in
patientswith SLE. Recently, acontrolled study
ofthe HPA axis in seven SLE patients showed
significant differences between the two groups
in cortisol secretion following insulin-induced
hypoglycemia (85). The involvement ofthe
HPG axishasalso been repeatedlysuspected in
SLE pathogenesis, in part because women are
affected approximately 10 times more often
than men. Pregnancy can be associated with
worsening ofsymptoms (59). Sex hormones
arerecognized asaffecting the immune system,
and estrogen appears to shift the immune
response toward a Th2-type response, thereby
potentially aggravating the severity ofanti-
body-mediated processes. In males with SLE,
the HPG axis functions similarly to that of
controls (86). Increased peripheral tissue aro-
matase activity resulting in greater estrogen
levels has been suggested as a potential factor
aggravating the course ofthe illness (87). The
potential negative effects ofestrogen on SLE
disease activity have raised questions as to the
safety ofprescribing oral contraceptives and
hormonal replacement therapy to women with
both active and inactive disease. Additionally,
there is increasing evidence that many environ-
mental compounds found in plants, insecti-
cides, and detergents have estrogenic activity
and may have effects on diseases such as breast
cancer (88). It is conceivable that these
substances could also impact SLE (89,90).
Prolactin has also been the subject of
interest in SLE because of its known
immunostimulatory properties (91). Elevated
serum levels have been variably reported in
SLE patients (92). As in the murine lupus
model, higher circulating levels ofprolactin
have been associated with greater autoanti-
body titers (93). Clinical trials ofbromocrip-
tine have had variable success in altering the
course ofthe disease (94,95).
Summary
Although our understanding of the
pathophysiology of autoimmune diseases
remains partial at best, it is clear that their
etiology is multifactorial. The neuro-
endocrine system is a good candidate as one
ofmany host susceptibility factors for auto-
immunity because of its role in rapidly
responding to a wide variety ofenvironmen-
tal exposures and quantitatively and qualita-
tively modulating the body's response to
them. Certainly, studies in animal models
support the importance ofthe stress response
in controlling the development ofinflamma-
tion. The interpretation of studies of the
neuroendocrine system in humans with
autoimmune disease remains difficult.
Indeed, because the study subjects already
have ongoing immune activation, a causal
relationship between disease susceptibility
and abnormal neuroendocrine profiles cannot
easily be inferred; it is not entirely clear
whether the observed changes precede the
onset ofillness or are its consequence. Animal
models in which premorbid neuroendocrine
activity can be studied suggest that such host
responses do play a role in inflammatory
resistance and susceptibility. Such models also
suggest that exposure to chronic stress (in a
variety offorms) and/or certain environmen-
tal agents can result in adaptation of the
organism's stress response and in suboptimal
or altered neuroendocrine activation to
immunogenic stimuli.
The fact that the neuroendocrine system is
key in controlling and dictating the stress
response to environmental exposures not only
makes it a good candidate as a susceptibility
factor for environmentally induced auto
immunity but may also account for some of
thevariability encountered when one attempts
to study such illnesses. Indeed, it iS critical to
keep in mind that multiple variables affect
neuroendocrine activation. This is particularly
important in the interpretation and design of
both animal and human studies examining
various aspects ofthe stress response. Thus, in
order to isolate as much as possible the poten-
tial effect of the exposure ofinterest, other
environmental factors that may impact neuro-
endocrine activation must be controlled for in
experimental design planning. Ultimately,
identification offactors relevant to induction
ofautoimmune disease will require the deter-
mination of multiple genetic factors (both
immune and nonimmune related genes), host
neuroendocrine and endocrine response sys-
tems, and characterization ofenvironmental
stimuli that can trigger disease.
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